Claims
- 1. A recombinant protein comprising an amino acid sequence corresponding to Kringle 1 to 5, a secretory signal peptide and a pre-activation peptide of a mammalian plasminogen.
- 2. A recombinant protein consisting essentially of an amino acid sequence corresponding to that of Kringle 1 to 5, a secretory signal peptide and a pre-activation peptide of a mammalian plasminogen.
- 3. A recombinant protein according to claim 1 having a molecular weight of between 55 kD and 69 kD.
- 4. A recombinant protein according to claim 3 having a molecular weight of about 65 kD.
- 5. A recombinant protein according to claim 1 having anti-angiogenic activity.
- 6. A recombinant protein according to claim 1 wherein said amino acid sequence has at least 70% identity with that shown in FIG. 6
- 7. A recombinant protein according to claim 5 further comprising a tumour targeting peptide.
- 8. A recombinant protein according to claim 7 wherein said tumour targeting peptide comprises an amino acid sequence selected from the group consisting of CNGRCVSGCAGCR and CDRGDCFC.
- 9. A nucleic acid sequence encoding a recombinant protein according to claim 1.
- 10. A nucleic acid sequence encoding a recombinant protein having an amino acid sequence corresponding to Kringle 1 to 5, a secretory signal peptide and a pre-activation peptide of a mammalian plasminogen, said sequence having at least 70% identity with the sequence between nucleotides 50 (codon start site ATG) and 1734 as shown in FIG. 1.
- 11. A nucleic acid sequence according to claim 9 which is cDNA
- 12. A replicable vector comprising nucleic acid according to claim 10 operably linked to control sequences to direct its expression.
- 13. A host cell transformed with the vector according to claim 12.
- 14. A method of producing a recombinant K1-5 polypeptide said method comprising culturing the host cell of claim 13 so that the recombinant K1-5 is produced.
- 15. A method according to claim 14 further comprising the step of recovering the recombinant protein produced.
- 16. A pharmaceutical composition comprising a recombinant protein according to claim 1.
- 17. A pharmaceutical composition comprising a nucleic acid sequence selected from the group consisting of a nucleic acid sequence encoding a recombinant protein comprising an amino acid sequence corresponding to Kringle 1 to 5, a secretory signal peptide and a pre-activation peptide of a mammalian plasminogen, a nucleic acid sequence comprising a replicable vector, said vector encoding a recombinant protein having an amino acid sequence corresponding to Kringle 1 to 5, a secretory signal peptide and a pre-activation peptide of a mammalian plasminogen, said recombinant protein encoding sequence having at least 70% identity with the sequence between nucleotides 50 (codon start site ATG) and 1734 as shown in FIG. 1 and a nucleic acid isolated from a host cell transformed with a nucleic acid sequence encoding a recombinant protein comprising an amino acid sequence corresponding to Kringle 1 to 5, a secretory signal peptide and a pre-activation peptide of a mammalian plasminogen.
- 18. A pharmaceutical composition according to claim 16 further comprising a pharmaceutically acceptable carrier.
- 19. A pharmaceutical composition according to claim 17 further comprising a pharmaceutically acceptable carrier.
- 20. A recombinant protein according to claim 1 for use in medical treatment.
- 21. A nucleic acid selected from the group consisting of of a nucleic acid sequence encoding a recombinant protein comprising an amino acid sequence corresponding to Kringle 1 to 5, a secretory signal peptide and a pre-activation peptide of a mammalian plasminogen, a nucleic acid sequence comprising a replicable vector, said vector encoding a recombinant protein having an amino acid sequence corresponding to Kringle 1 to 5, a secretory signal peptide and a pre-activation peptide of a mammalian plasminogen, said recombinant protein encoding sequence having at least 70% identity with the sequence between nucleotides 50 (codon start site ATG) and 1734 as shown in FIG. 1 and a nucleic acid isolated from a host cell transformed with a nucleic acid sequence encoding a recombinant protein comprising an amino acid sequence corresponding to Kringle 1 to 5, a secretory signal peptide and a pre-activation peptide of a mammalian plasminogen for use in medical treatment.
- 22. A method of treating a patient in need of anti-angiogenic therapy comprising administering to that patient an effective dose of a pharmaceutical composition according to claim 16.
- 23. A method of treating a patient in need of anti-angiogenic therapy comprising administering to that patient an effective dose of a pharmaceutical composition according to claim 17.
- 24. A method of treating a patient in need of anti angiogenic therapy comprising transfecting cells with a vector comprising a nucleic acid sequence according to claim 10, selecting those cells successfully transfected, expanding the number of transfected cells, and implanting said transfected cells into the patient.
- 25. A method according to claim 24 wherein said cells were previously obtained from said patient.
- 26. A method according to claim 25 wherein said cells are selected from the group consisting of peripheral and tumour-infiltrating lymphocytes, hepatocytes, epidermal cells, myocytes and other somatic cells.
- 27. A method of treating a patient in need of anti-angiogenic therapy comprising administering to said patient a viral vector comprising nucleic acid according to claim 9.
- 28. A method according to claim 27 wherein said vector is a retroviral vector.
- 29. An antibody capable of specifically binding to a recombinant protein according to claim 1.
- 30. An antibody according to claim 29 further comprising a label.
- 31. A pharmaceutical composition comprising an antibody according to claim 30.
Parent Case Info
[0001] This application claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Application 60/230,893 filed Sep. 5, 2000, the entire disclosure of which is incorporated by reference herein.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60230893 |
Sep 2000 |
US |